
Opinion|Videos|December 5, 2025
Role of Age and Ph Status in Blinatumomab Selection in ALL
Author(s)Jonathan Webster, MD, Nikesh Shah, MD
Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL.
Advertisement
Episodes in this series

Jonathan Webster, MD, and Nikesh Shah, MD, describe how patient age and Philadelphia chromosome (Ph) status influence the decision to incorporate blinatumomab (Blincyto) into an ALL treatment plan. They discuss how younger adults, older adults, and patients with Ph-positive or Ph-negative disease may derive different levels of benefit based on disease biology and treatment tolerance. They also outline how these factors guide personalized treatment algorithms and optimize therapeutic outcomes.
Advertisement
Related to this article

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5

